Morgan Stanley’s iBio IBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $58.8K | Buy |
30,937
+3,342
| +12% | +$7.75K | ﹤0.01% | 6362 |
|
|
2025
Q4 | $53.3K | Buy |
27,595
+27,538
| +48,312% | +$37.6K | ﹤0.01% | 6413 |
|
|
2025
Q3 | $47 | Buy |
57
+8
| +16% | +$6 | ﹤0.01% | 7866 |
|
|
2025
Q2 | $38 | Sell |
49
-3,726
| -99% | -$4.04K | ﹤0.01% | 7867 |
|
|
2025
Q1 | $15.2K | Buy |
3,775
+3,727
| +7,765% | +$14.5K | ﹤0.01% | 6660 |
|
|
2024
Q4 | $117 | Hold |
48
| – | – | ﹤0.01% | 7454 |
|
|
2024
Q3 | $107 | Sell |
48
-1
| -2% | -$2 | ﹤0.01% | 7432 |
|
|
2024
Q2 | $103 | Sell |
49
-219
| -82% | -$471 | ﹤0.01% | 7345 |
|
|
2024
Q1 | $1.09K | Sell |
268
-410
| -60% | -$515 | ﹤0.01% | 7164 |
|
|
2023
Q4 | $928 | Buy |
678
+315
| +87% | +$1.38K | ﹤0.01% | 7213 |
|
|
2023
Q3 | $2.2K | Buy |
363
+5
| +1% | +$43 | ﹤0.01% | 7109 |
|
|
2023
Q2 | $4.36K | Buy |
358
+256
| +251% | +$4.83K | ﹤0.01% | 7017 |
|
|
2023
Q1 | $4.23K | Sell |
102
-255
| -71% | -$6.56K | ﹤0.01% | 7091 |
|
|
2022
Q4 | $3.17K | Buy |
357
+234
| +190% | +$7.92K | ﹤0.01% | 7258 |
|
|
2022
Q3 | $11K | Sell |
123
-544
| -82% | -$74.9K | ﹤0.01% | 7040 |
|
|
2022
Q2 | $88K | Buy |
667
+363
| +119% | +$54.6K | ﹤0.01% | 6344 |
|
|
2022
Q1 | $64K | Sell |
304
-15
| -5% | -$3.14K | ﹤0.01% | 6575 |
|
|
2021
Q4 | $86K | Buy |
319
+58
| +22% | +$22.1K | ﹤0.01% | 6527 |
|
|
2021
Q3 | $138K | Sell |
261
-64
| -20% | -$39.9K | ﹤0.01% | 6193 |
|
|
2021
Q2 | $244K | Buy |
325
+116
| +56% | +$84.6K | ﹤0.01% | 5911 |
|
|
2021
Q1 | $161K | Sell |
209
-406
| -66% | -$354K | ﹤0.01% | 5776 |
|
|
2020
Q4 | $323K | Sell |
615
-6
| -1% | -$4.89K | ﹤0.01% | 5329 |
|
|
2020
Q3 | $631K | Buy |
621
+561
| +935% | +$813K | ﹤0.01% | 4517 |
|
|
2020
Q2 | $67K | Buy |
60
+53
| +757% | +$34.7K | ﹤0.01% | 5567 |
|
|
2020
Q1 | $4K | Buy |
7
+5
| +250% | +$1.92K | ﹤0.01% | 6268 |
|
|
2019
Q4 | $0 | Sell |
2
-1
| -33% | -$136 | ﹤0.01% | 6692 |
|
|
2019
Q3 | $1K | Hold |
3
| – | – | ﹤0.01% | 6545 |
|
|
2019
Q2 | $1K | Hold |
3
| – | – | ﹤0.01% | 6542 |
|
|
2019
Q1 | $1K | Hold |
3
| – | – | ﹤0.01% | 6514 |
|
|
2018
Q4 | $1K | Hold |
3
| – | – | ﹤0.01% | 6501 |
|
|
2018
Q3 | $1K | Hold |
3
| – | – | ﹤0.01% | 6625 |
|
|
2018
Q2 | $1K | Hold |
3
| – | – | ﹤0.01% | 6589 |
|
|
2018
Q1 | $3K | Hold |
3
| – | – | ﹤0.01% | 6453 |
|
|
2017
Q4 | $3K | Hold |
3
| – | – | ﹤0.01% | 6397 |
|
|
2017
Q3 | $5K | Hold |
3
| – | – | ﹤0.01% | 6290 |
|
|
2017
Q2 | $7K | Buy |
3
+1
| +50% | +$1.96K | ﹤0.01% | 6300 |
|
|
2017
Q1 | $4K | Hold |
2
| – | – | ﹤0.01% | 6383 |
|
|
2016
Q4 | $4K | Hold |
2
| – | – | ﹤0.01% | 6301 |
|
|
2016
Q3 | $6K | Hold |
2
| – | – | ﹤0.01% | 6200 |
|
|
2016
Q2 | $9K | Hold |
2
| – | – | ﹤0.01% | 6082 |
|
|
2016
Q1 | $7K | Hold |
2
| – | – | ﹤0.01% | 6209 |
|
|
2015
Q4 | $6K | Sell |
2
-1
| -33% | -$3.19K | ﹤0.01% | 6342 |
|
|
2015
Q3 | $10K | Hold |
3
| – | – | ﹤0.01% | 6237 |
|
|
2015
Q2 | $14K | Buy |
3
+2
| +200% | +$9.3K | ﹤0.01% | 6219 |
|
|
2015
Q1 | $5K | Hold |
1
| – | – | ﹤0.01% | 6339 |
|
|
2014
Q4 | $4K | Buy |
+1
| New | +$5.34K | ﹤0.01% | 6367 |
|
|
2014
Q3 | – | Sell |
-1
| Closed | -$2K | – | 6604 |
|
|
2014
Q2 | $2K | Sell |
1
-1
| -50% | -$2.16K | ﹤0.01% | 6386 |
|
|
2014
Q1 | $5K | Hold |
2
| – | – | ﹤0.01% | 6244 |
|
|
2013
Q4 | $3K | Buy |
+2
| New | +$3.64K | ﹤0.01% | 6217 |
|
Other funds holding IBIO
AAA
FLSM
EC
LGM
VCM
IC
SCM
Morgan Stanley's IBIO Position: Q1 2026 in Review
Morgan Stanley increased its iBio (IBIO) stake by 12% in Q1 2026, buying an estimated $7.75K and bringing the position to 30,937 shares worth $58.8K. The position accounts for ﹤0.01% of the portfolio, ranked #6362.
Morgan Stanley first reported a position in IBIO in Q4 2013 and has held it in 49 quarters since. The position peaked at $631K in Q3 2020. 52 funds tracked by Wall St. Rank hold IBIO as of Q1 2026.
- Morgan Stanley held 30,937 shares of iBio worth $58.8K as of Q1 2026.
- Morgan Stanley bought 3,342 iBio shares in Q1 2026, an estimated $7.75K.
- iBio made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6362 holding.
- Morgan Stanley first reported a position in iBio in Q4 2013 and has held it in 49 quarters since.
- Morgan Stanley's iBio position peaked at $631K in Q3 2020.
- 52 funds tracked by Wall St. Rank held iBio as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.